Magnetic resonance spectroscopic imaging of benign prostatic tissue: Findings at 3.0 T compared to 1.5 T-initial experience

Clinical Imaging

Volumn 35, Issue 4, 2011, Pages 288-293

  Chitkara, Munish ^a   Westphalen, Antonio ^a   Kurhanewicz, John ^a   Qayyum, Aliya ^a   Poder, Liina ^a   Reed, Galen ^a   Coakley, Fergus V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

3 T; Cancer; MR; MR spectroscopy; Prostate

Indexed keywords

3 T; CANCER; MR; MR SPECTROSCOPY; PROSTATE;

DISEASES; MAGNETIC RESONANCE SPECTROSCOPY; TISSUE;

MAGNETIC RESONANCE;

CHOLINE; CITRIC ACID; CREATINE; POLYAMINE;

ADULT; AGED; ARTICLE; BENIGN PERIPHERAL ZONE PROSTATE TISSUE; CHOLINE TO CITRATE INTEGRAL PEAK RATIO; CLINICAL ARTICLE; CREATINE TO CITRATE INTEGRAL PEAK; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POLYAMINE TO CITRATE INTEGRAL PEAK RATIO; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY;

CHOLINE; CITRIC ACID; CREATINE; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; POLYAMINES; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 79959836532     PISSN: 08997071     EISSN: 18734499     Source Type: Journal    
DOI: 10.1016/j.clinimag.2010.07.005     Document Type: Article

References (19)

1. Coakley FV, Qayyum A, Kurhanewicz J Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J. Urol 2003, 170:S69-S76.
2. Cabrera AR, Coakley FV, Westphalen AC, Lu Y, Zhao S, Shinohara K, Carroll PR, Kurhanewicz J Prostate cancer: is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance?. Radiology 2008, 247:444-450.
3. Shukla-Dave A, Hricak H, Moskowitz C, Ishill N, Akin O, Kuroiwa K, Spector J, Kumar M, Reuter VE, Koutcher JA, Zakian KL Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology 2007, 245:499-506.
4. Gambarota G, van der Graaf M, Klomp D, Mulkern RV, Heerschap A Echo-time independent signal modulations using PRESS sequences: a new approach to spectral editing of strongly coupled AB spin systems. J Magn Reson 2005, 177:299-306.
5. Star-Lack J, Vigneron DB, Pauly J, Kurhanewicz J, Nelson SJ Improved solvent suppression and increased spatial excitation bandwidths for three-dimensional PRESS CSI using phase-compensating spectral/spatial spin-echo pulses. J Magn Reson Imaging 1997, 7:745-757.
6. Schricker AA, Pauly JM, Kurhanewicz J, Swanson MG, Vigneron DB Dualband spectral-spatial RF pulses for prostate MR spectroscopic imaging. Magn Reson Med 2001, 46:1079-1087.
7. Tran T-KC, Vigneron DB, Sailasuta N, et al. Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn Reson Med 2000, 43:23-33.
8. Chen AP, Cunningham CH, Ozturk-Isik E, Xu D, Hurd RE, Kelley DA, Pauly JM, Kurhanewicz J, Nelson SJ, Vigneron DB High-speed 3T MR spectroscopic imaging of prostate with flyback echo-planar encoding. J Magn Reson Imaging 2007, 25:1288-1292.
9. Wefer AE, Hricak H, Vigneron DB, Coakley FV, Lu Y, Wefer J, Mueller-Lisse U, Carroll PR, Kurhanewicz J Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000, 164:400-404.
10. Jung JA, Coakley FV, Vigneron DB, Swanson MG, Qayyum A, Weinberg V, Jones KD, Carroll PR, Kurhanewicz J Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004, 233:701-708.
11. Cunningham CH, Vigneron DB, Marjanska M, et al. Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T. Magn Reson Med 2005, 53:1033-1039.
12. Swanson MG, Vigneron DB, Tabatabai ZL, et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med 2003, 50:944-954.
13. Swanson MG, Zektzer AS, Tabatabai ZL, et al. Quantitative analysis of prostate metabolites using (1)H HR-MAS spectroscopy. Magn Reson Med 2006, 55:1257-1264.
14. Hussain SM, Wielopolski PA, Martin DR Abdominal magnetic resonance imaging at 3.0 T: problem or a promise for the future?. Top Magn Reson Imaging 2005, 16:325-335.
15. Barth MM, Smith MP, Pedrosa I, Lenkinski RE, Rofsky NM Body MR imaging at 3.0 T: understanding the opportunities and challenges. Radiographics 2007, 27:1445-1462.
16. Barker PB, Hearshen DO, Boska MD Single-voxel proton MRS of the human brain at 1.5T and 3.0T. Magn Reson Med 2001, 45:765-769.
17. Zeng QS, Li CF, Zhang K, Liu H, Kang XS, Zhen JH Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. J Neurooncol 2007, 84:63-69.
18. Weybright P, Sundgren PC, Maly P, Hassan DG, Nan B, Rohrer S, Junck L Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol 2005, 185:1471-1476.
19. Testa C, Schiavina R, Lodi R, Salizzoni E, Corti B, Farsad M, Kurhanewicz J, Manferrari F, Brunocilla E, Tonon C, Monetti N, Castellucci P, Fanti S, Coe M, Grigioni WF, Martorana G, Canini R, Barbiroli B Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 2007, 244:797-806.